Reversing Feedback Immunosuppression during Oncolytic Virotherapy of Pediatric High Grade Glioma |
Augusta University Research Institute, Inc. / Bangxing Hong, PhD |
Reach Grants |
2023 |
Georgia |
Targeting Novel Pediatric-Specific FLT3 Mutations |
Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD,PhD |
Reach Grants |
2015 |
Washington |
Stroma Biology Identifies Heparin as a Differentiating Agent in Neuroblastoma
|
Duke University Medical Center / Gerard Blobe, MD, PhD |
Reach Grants |
2013 |
North Carolina |
Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemias |
National Cancer Institute / Andre Nussenzweig, Ph.D. |
Reach Grants |
2014 |
Maryland |
Targeting Chondroitin Sulphate Proteoglycan 4 (CSPG4) in Glioblastoma |
University of North Carolina / Gianpietro Dotti, MD & Barbara Savoldo, MD/PhD |
Reach Grants |
2017 |
North Carolina |
Preclinical Development of a First-in-Class PCNA Inhibitor for Treating Neuroblastoma |
City of Hope National Medical Center / Linda Malkas, PhD |
Reach Grants |
2019 |
California |
Optimization of Drug Efflux and Brain Clearance to Improve CED of Targeted Therapy to H3K27M DMG |
Mayo Clinic / David Daniels, MD/PhD |
Reach Grants |
2021 |
Minnesota |
Astatine-211 Meta-Astatobenzylguanidine ([211At]MABG) Targeted Radiotherapy for Disseminated Neuroblastoma |
Children’s Hospital of Philadelphia / John Maris, MD |
Reach Grants |
2016 |
Pennsylvania |
Identifying a Therapeutic Partner for TAK228 for Pediatric Phase II Brain Tumor Studies |
The Johns Hopkins University School of Medicine / Eric H. Raabe, MD/PhD |
Reach Grants |
2018 |
Maryland |
Generation of CMV-specific CD19 CAR T cells Using Cytokine Capture Followed by Lentiviral Transduction and Expansion |
Research Institute at Nationwide Children's Hospital / Margaret Lamb, MD |
Reach Grants |
2019 |
Ohio |